Luteinizing Hormone Monitoring in Transfeminine Hormone Therapy
Luteinizing hormone (LH) monitoring serves as a useful adjunct marker for assessing testosterone suppression in transfeminine individuals, particularly after orchiectomy or in those not taking GnRH agonists, though testosterone measurement remains the primary monitoring parameter. 1
Primary Monitoring Strategy
The cornerstone of monitoring feminizing gender-affirming hormone therapy (GAHT) focuses on achieving testosterone suppression to the female range (<50 ng/dL) rather than targeting specific estradiol levels. 2 The evidence demonstrates that:
- Testosterone concentrations inversely correlate with estradiol levels during feminizing GAHT (P < .001), making testosterone the more reliable primary monitoring parameter. 1
- Factors including orchiectomy status, age, and spironolactone use significantly affect testosterone levels but not estradiol concentrations (P < .001), further supporting testosterone as the preferred monitoring target. 1
Role of LH in Specific Clinical Contexts
Post-Orchiectomy Patients
In transfeminine individuals who have undergone orchiectomy and are not taking GnRH agonists, LH monitoring becomes particularly valuable as a secondary marker. 1 This is because:
- Changes in testosterone concentrations correlate with changes in LH levels (P < .05) in this population. 1
- After gonadectomy, the LH response to estrogen administration shifts to match the hormonal environment rather than genetic sex, demonstrating that LH feedback mechanisms adapt to the new endocrine milieu. 3
Patients with Intact Gonads
In transfeminine individuals with intact testes:
- LH suppression occurs alongside testosterone suppression during estrogen therapy, though the degree varies with estrogen dose. 4
- High-dose estrogen significantly suppresses LH levels, while lower doses may not achieve complete LH suppression despite adequate testosterone reduction. 4
- The absence of positive estrogen feedback on LH secretion in genetic males taking feminizing GAHT (unlike in genetic females) reflects the hormonal environment rather than an intrinsic sex-specific response. 5, 3
Practical Monitoring Algorithm
For transfeminine patients with intact gonads:
- Monitor serum testosterone as the primary parameter, targeting <50 ng/dL. 2
- Measure estradiol to ensure adequate dosing (adult female range), though recognize its limitations as a monitoring tool. 1
- LH measurement is optional but may provide additional information about hypothalamic-pituitary-gonadal axis suppression. 1
For post-orchiectomy patients not on GnRH agonists:
- Continue monitoring testosterone levels as the primary marker. 1
- Consider adding LH monitoring as it becomes more clinically relevant in this population for assessing hormonal adequacy. 1
- LH can help determine if estrogen dosing is sufficient to maintain appropriate feedback suppression. 1
Clinical Caveats
The relationship between LH and feminizing GAHT has important limitations:
- LH response to estrogen is not sex-specific in humans but depends on the current hormonal environment, meaning it reflects treatment effects rather than inherent biological sex. 3
- Historical studies attempting to use LH responses to distinguish between heterosexual and transsexual individuals have been contradicted by evidence showing hormonal environment determines response patterns. 5, 3
- In critically ill transfeminine patients, the hypothalamic-pituitary-adrenal axis interactions with GAHT become complex, though specific evidence-based monitoring guidelines are lacking. 6
Why Testosterone Remains Primary
Despite LH's utility in specific contexts, testosterone monitoring maintains primacy because:
- Orchiectomy status, spironolactone use, and age all independently affect testosterone but not estradiol levels, making testosterone a more sensitive marker of treatment adequacy. 1
- The clinical goal of feminizing GAHT is testosterone suppression to achieve feminine physical characteristics (breast development, decreased facial/body hair, feminized body composition). 2
- Testosterone suppression directly correlates with desired physical outcomes, whereas LH serves as an indirect marker of hypothalamic-pituitary suppression. 1